{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:58:07Z","timestamp":1785455887554,"version":"3.56.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["843107"],"award-info":[{"award-number":["843107"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["40028133"],"award-info":[{"award-number":["40028133"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["400008574"],"award-info":[{"award-number":["400008574"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["40028944"],"award-info":[{"award-number":["40028944"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Esophageal squamous cell carcinoma (eSCC) is a highly aggressive malignancy with poor prognosis and limited therapeutic options. Although immune checkpoint inhibitors such as nivolumab have shown clinical benefit, particularly in patients with high PD-L1 expression, this subgroup represents only a small fraction of eSCC cases. CDK4\/6 inhibitors such as palbociclib have only been tested as second-line agents in eSCC, often in combination with EGFR inhibitors, with minimal benefit. Our study evaluates palbociclib as a first-line therapy in treatment-naive eSCC models. Using a panel of 22 eSCC cell lines with integrated multi-omics and phenotypic assays, we identified three response subtypes, resistant, delayed, and arrested, correlated to Rb-pathway status. Interestingly, in delayed responders, palbociclib treatment was associated with DNA damage accumulation and unprotected micronuclei enriched for cGAS, triggering activation of interferon-stimulated genes. Consistent with this, palbociclib enhanced immune cell infiltration in delayed eSCC spheroids within a preclinical vascularized 3D microfluidic system. Our study demonstrates that first-line palbociclib treatment unmasks intrinsic vulnerabilities in the CDK4\/6-Rb axis and triggers innate immune activation in molecularly defined eSCC. Using a translationally relevant 3D vascularized microfluidic system, we provide evidence that early CDK4\/6 inhibition not only stall cancer cell growth but also promotes immune cells recruitment. In conclusion, our study identifies palbociclib as a viable first-line therapeutic candidate in selected eSCC patients and uncover its immunomodulatory potential.<\/jats:p>","DOI":"10.1038\/s41419-026-08892-x","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:39:54Z","timestamp":1780069194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CDK4\/6 inhibition uncovers subtype-specific vulnerabilities and immune-related responses in esophageal squamous cell carcinoma"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1244-5571","authenticated-orcid":false,"given":"Fabiana","family":"Moresi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Jap\u00f3n-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9406-0679","authenticated-orcid":false,"given":"Matteo","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9511-9711","authenticated-orcid":false,"given":"Marta","family":"\u00c1valos-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloine","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Coulonval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pavesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8896-5098","authenticated-orcid":false,"given":"Xavier","family":"Bisteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"8892_CR1","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","volume":"33","author":"R Obermannov\u00e1","year":"2022","unstructured":"Obermannov\u00e1 R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, et al. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up \u2729. Ann Oncol. 2022;33:992\u20131004. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.003.","journal-title":"Ann Oncol"},{"key":"8892_CR2","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/cac2.12457","volume":"43","author":"M Matz","year":"2023","unstructured":"Matz M, Valkov M, \u0160ekerija M, Luttman S, Caldarella A, Coleman MP, et al. Worldwide trends in esophageal cancer survival, by sub-site, morphology, and sex: an analysis of 696,974 adults diagnosed in 60 countries during 2000-2014 (CONCORD-3). Cancer Commun. 2023;43:963\u201380. https:\/\/doi.org\/10.1002\/cac2.12457.","journal-title":"Cancer Commun"},{"key":"8892_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2022.12.004","volume":"41","author":"Z Liu","year":"2023","unstructured":"Liu Z, Zhao Y, Kong P, Liu Y, Huang J, Xu E, et al. Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma. Cancer Cell. 2023;41:181\u201395.e9. https:\/\/doi.org\/10.1016\/j.ccell.2022.12.004.","journal-title":"Cancer Cell"},{"key":"8892_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1171671","volume":"14","author":"Y Lu","year":"2023","unstructured":"Lu Y, Wang W, Wang F. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials. Front Immunol. 2023;14:1171671. https:\/\/doi.org\/10.3389\/fimmu.2023.1171671.","journal-title":"Front Immunol"},{"key":"8892_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20019-0","volume":"11","author":"Y Zheng","year":"2020","unstructured":"Zheng Y, Chen Z, Han Y, Han L, Zou X, Zhou B, et al. Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment. Nat Commun. 2020;11:6268. https:\/\/doi.org\/10.1038\/s41467-020-20019-0.","journal-title":"Nat Commun"},{"key":"8892_CR6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3390\/curroncol30010048","volume":"30","author":"U Testa","year":"2023","unstructured":"Testa U, Castelli G, Pelosi E. The molecular characterization of genetic abnormalities in esophageal squamous cell carcinoma may foster the development of targeted therapies. Curr Oncol. 2023;30:610\u201340. https:\/\/doi.org\/10.3390\/curroncol30010048.","journal-title":"Curr Oncol"},{"key":"8892_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature13176","volume":"509","author":"Y Song","year":"2014","unstructured":"Song Y, Li L, Ou Y, Gao Z, Li E, Li X, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509:91\u20135. https:\/\/doi.org\/10.1038\/nature13176.","journal-title":"Nature"},{"key":"8892_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature20805","volume":"541","author":"J Kim","year":"2017","unstructured":"Kim J, Bowlby R, Mungall AJ, Robertson AG, Odze RD, Cherniack AD, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541:169\u201375. https:\/\/doi.org\/10.1038\/nature20805.","journal-title":"Nature"},{"key":"8892_CR9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1053\/j.gastro.2017.06.066","volume":"154","author":"D-C Lin","year":"2018","unstructured":"Lin D-C, Wang M-R, Koeffler HP. Genomic and epigenomic aberrations in esophageal squamous cell carcinoma and implications for patients. Gastroenterology. 2018;154:374\u201389. https:\/\/doi.org\/10.1053\/j.gastro.2017.06.066.","journal-title":"Gastroenterology"},{"key":"8892_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10549-024-07287-w","volume":"206","author":"N Mart\u00ednez-Ja\u00f1ez","year":"2024","unstructured":"Mart\u00ednez-Ja\u00f1ez N, Ezquerra MB, Sanchez LMM, Carrasco FH, Torres AA, Morales S, et al. First-line therapy with palbociclib in patients with advanced HR+\/HER2\u2212 breast cancer: the real-life study PALBOSPAIN. Breast Cancer Res Treat. 2024;206:317\u201328. https:\/\/doi.org\/10.1007\/s10549-024-07287-w.","journal-title":"Breast Cancer Res Treat"},{"key":"8892_CR11","doi-asserted-by":"publisher","unstructured":"Karasic TB, O\u2019Hara MH, Teitelbaum UR, Damjanov N, Giantonio BJ, d\u2019Entremont TS, et al. Phase II trial of palbociclib in patients with advanced esophageal or gastric cancer. Oncol. 2020. https:\/\/doi.org\/10.1634\/theoncologist.2020-0681.","DOI":"10.1634\/theoncologist.2020-0681"},{"key":"8892_CR12","doi-asserted-by":"publisher","first-page":"1041.","DOI":"10.1038\/s42003-023-05412-x","volume":"6","author":"H Fan","year":"2023","unstructured":"Fan H, Liu W, Zeng Y, Zhou Y, Gao M, Yang L, et al. DNA damage induced by CDK4 and CDK6 blockade triggers anti-tumor immune responses through cGAS-STING pathway. Commun Biol. 2023;6:1041. https:\/\/doi.org\/10.1038\/s42003-023-05412-x.","journal-title":"Commun Biol"},{"key":"8892_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/1878-0261.13541","volume":"18","author":"DH Lee","year":"2024","unstructured":"Lee DH, Imran M, Choi JH, Park YJ, Kim YH, Min S, et al. CDK4\/6 inhibitors induce breast cancer senescence with enhanced anti-tumor immunogenic properties compared with DNA-damaging agents. Mol Oncol. 2024;18:216\u201332. https:\/\/doi.org\/10.1002\/1878-0261.13541.","journal-title":"Mol Oncol"},{"key":"8892_CR14","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1158\/1541-7786.mcr-18-0201","volume":"16","author":"AC Chaikovsky","year":"2018","unstructured":"Chaikovsky AC, Sage J. Beyond the cell cycle: enhancing the immune surveillance of tumors via CDK4\/6 inhibition. Mol Cancer Res. 2018;16:1454\u20137. https:\/\/doi.org\/10.1158\/1541-7786.mcr-18-0201.","journal-title":"Mol Cancer Res"},{"key":"8892_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03351-z","volume":"24","author":"X Cai","year":"2024","unstructured":"Cai X, Yin G, Chen S, Tacke F, Guillot A, Liu H. CDK4\/6 inhibition enhances T-cell immunotherapy on hepatocellular carcinoma cells by rejuvenating immunogenicity. Cancer Cell Int. 2024;24:215. https:\/\/doi.org\/10.1186\/s12935-024-03351-z.","journal-title":"Cancer Cell Int"},{"key":"8892_CR16","first-page":"1616","volume":"14","author":"W-J Qin","year":"2022","unstructured":"Qin W-J, Su Y-G, Ding X-L, Zhao R, Zhao Z-J, Wang Y-Y. CDK4\/6 inhibitor enhances the radiosensitization of esophageal squamous cell carcinoma (ESCC) by activating autophagy signaling via the suppression of mTOR. Am J Transl Res. 2022;14:1616\u201327.","journal-title":"Am J Transl Res"},{"key":"8892_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1231-7","volume":"15","author":"J Wang","year":"2017","unstructured":"Wang J, Li Q, Yuan J, Wang J, Chen Z, Liu Z, et al. CDK4\/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest. J Transl Med. 2017;15:127. https:\/\/doi.org\/10.1186\/s12967-017-1231-7.","journal-title":"J Transl Med"},{"key":"8892_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41577-024-01011-x","volume":"24","author":"G Adriani","year":"2024","unstructured":"Adriani G, Pavesi A. The OrganiX microfluidic system to recreate the complex tumour microenvironment. Nat Rev Immunol. 2024;24:307 https:\/\/doi.org\/10.1038\/s41577-024-01011-x.","journal-title":"Nat Rev Immunol"},{"key":"8892_CR19","doi-asserted-by":"publisher","first-page":"e92444","DOI":"10.1371\/journal.pone.0092444","volume":"9","author":"C Guzm\u00e1n","year":"2014","unstructured":"Guzm\u00e1n C, Bagga M, Kaur A, Westermarck J, Abankwa D. ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS ONE. 2014;9:e92444 https:\/\/doi.org\/10.1371\/journal.pone.0092444.","journal-title":"PLoS ONE"},{"key":"8892_CR20","doi-asserted-by":"publisher","first-page":"e0146021","DOI":"10.1371\/journal.pone.0146021","volume":"10","author":"C Ritz","year":"2015","unstructured":"Ritz C, Baty F, Streibig JC, Gerhard D. Dose-response analysis using R. PLoS ONE. 2015;10:e0146021 https:\/\/doi.org\/10.1371\/journal.pone.0146021.","journal-title":"PLoS ONE"},{"key":"8892_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/0003-2697(90)90134-u","volume":"190","author":"LS Minamide","year":"1990","unstructured":"Minamide LS, Bamburg JR. A filter paper dye-binding assay for quantitative determination of protein without interference from reducing agents or detergents. Anal Biochem. 1990;190:66\u201370. https:\/\/doi.org\/10.1016\/0003-2697(90)90134-u.","journal-title":"Anal Biochem"},{"key":"8892_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/s0014-4827(03)00392-6","volume":"291","author":"K Coulonval","year":"2003","unstructured":"Coulonval K, Bockstaele L, Paternot S, Dumont JE, Roger PP. The cyclin D3-CDK4-p27kip1 holoenzyme in thyroid epithelial cells: activation by TSH, inhibition by TGF\u03b2, and phosphorylations of its subunits demonstrated by two-dimensional gel electrophoresis. Exp Cell Res. 2003;291:135\u201349. https:\/\/doi.org\/10.1016\/s0014-4827(03)00392-6.","journal-title":"Exp Cell Res"},{"key":"8892_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1747-1028-1-25","volume":"1","author":"L Bockstaele","year":"2006","unstructured":"Bockstaele L, Coulonval K, Kooken H, Paternot S, Roger PP. Regulation of CDK4. Cell Div. 2006;1:25. https:\/\/doi.org\/10.1186\/1747-1028-1-25.","journal-title":"Cell Div"},{"key":"8892_CR24","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.15252\/emmm.201607084","volume":"9","author":"E Rasp\u00e9","year":"2017","unstructured":"Rasp\u00e9 E, Coulonval K, Pita JM, Paternot S, Roth\u00e9 F, Twyffels L, et al. CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib. Embo Mol Med. 2017;9:1052\u201366. https:\/\/doi.org\/10.15252\/emmm.201607084.","journal-title":"Embo Mol Med"},{"key":"8892_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8.","journal-title":"Genome Biol"},{"key":"8892_CR26","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1093\/bioinformatics\/bty895","volume":"35","author":"A Zhu","year":"2018","unstructured":"Zhu A, Ibrahim JG, Love MI. Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. Bioinformatics. 2018;35:2084\u201392. https:\/\/doi.org\/10.1093\/bioinformatics\/bty895.","journal-title":"Bioinformatics"},{"key":"8892_CR27","doi-asserted-by":"publisher","unstructured":"Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Sergushichev A. Fast gene set enrichment analysis. bioRxiv [Preprint]. 2021. Available from: https:\/\/doi.org\/10.1101\/060012","DOI":"10.1101\/060012"},{"key":"8892_CR28","doi-asserted-by":"publisher","unstructured":"Schmidt U, Weigert M, Broaddus C, Myers G. Medical Image Computing and Computer Assisted Intervention \u2013 MICCAI 2018, 21st International Conference, Granada, Spain, Proceedings, Part II. Lect Notes Comput Sci 2018;265\u2013273. https:\/\/doi.org\/10.1007\/978-3-030-00934-2_30.","DOI":"10.1007\/978-3-030-00934-2_30"},{"key":"8892_CR29","doi-asserted-by":"publisher","first-page":"378","DOI":"10.32614\/rj-2017-066","volume":"9","author":"ME Brooks","year":"2017","unstructured":"Brooks ME, Kristensen K, van Benthem KJ, Magnusson A, Berg CW, Nielsen A, et al. glmmTMB balances speed and flexibility among packages for zero-inflated generalized linear mixed modeling. R J. 2017;9:378 https:\/\/doi.org\/10.32614\/rj-2017-066.","journal-title":"R J"},{"key":"8892_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1156769","volume":"13","author":"G Giustarini","year":"2023","unstructured":"Giustarini G, Teng G, Pavesi A, Adriani G. Characterization of 3D heterocellular spheroids of pancreatic ductal adenocarcinoma for the study of cell interactions in the tumor immune microenvironment. Front Oncol. 2023;13:1156769. https:\/\/doi.org\/10.3389\/fonc.2023.1156769.","journal-title":"Front Oncol"},{"key":"8892_CR31","doi-asserted-by":"publisher","unstructured":"Wobbrock JO, Findlater L, Gergle D, Higgins JJ. The aligned rank transform for nonparametric factorial analyses using only ANOVA procedures. In: Proceedings of the SIGCHI conference on human factors in computing systems. 2011. p. 143\u20136. https:\/\/doi.org\/10.1145\/1978942.1978963","DOI":"10.1145\/1978942.1978963"},{"key":"8892_CR32","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.1093\/bioinformatics\/btaa1018","volume":"36","author":"X Lu","year":"2020","unstructured":"Lu X, Meng J, Zhou Y, Jiang L, Yan F. MOVICS: an R package for multi-omics integration and visualization in cancer subtyping. Bioinformatics. 2020;36:5539\u201341. https:\/\/doi.org\/10.1093\/bioinformatics\/btaa1018.","journal-title":"Bioinformatics"},{"key":"8892_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/biostatistics\/kxx017","volume":"19","author":"Q Mo","year":"2018","unstructured":"Mo Q, Shen R, Guo C, Vannucci M, Chan KS, Hilsenbeck SG. A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. Biostatistics. 2018;19:71\u201386. https:\/\/doi.org\/10.1093\/biostatistics\/kxx017.","journal-title":"Biostatistics"},{"key":"8892_CR34","doi-asserted-by":"publisher","first-page":"e1003546","DOI":"10.1371\/journal.pgen.1003546","volume":"9","author":"X Bisteau","year":"2013","unstructured":"Bisteau X, Paternot S, Colleoni B, Ecker K, Coulonval K, Groote PD, et al. CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4\/CDK2 interplay mediated by p21 phosphorylation at the restriction point. PLoS Genet. 2013;9:e1003546 https:\/\/doi.org\/10.1371\/journal.pgen.1003546.","journal-title":"PLoS Genet"},{"key":"8892_CR35","doi-asserted-by":"publisher","first-page":"689","DOI":"10.4161\/cc.9.4.10611","volume":"9","author":"S Paternot","year":"2010","unstructured":"Paternot S, Bockstaele L, Bisteau X, Kooken H, Coulonval K, Roger P. Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase. Cell Cycle. 2010;9:689\u201399. https:\/\/doi.org\/10.4161\/cc.9.4.10611.","journal-title":"Cell Cycle"},{"key":"8892_CR36","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/1878-0261.13351","volume":"18","author":"S Paternot","year":"2024","unstructured":"Paternot S, Rasp\u00e9 E, Meiller C, Tarabichi M, Assi\u00e9 J, Libert F, et al. Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4\/6 inhibition. Mol Oncol. 2024;18:866\u201394. https:\/\/doi.org\/10.1002\/1878-0261.13351.","journal-title":"Mol Oncol"},{"key":"8892_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1247542","volume":"14","author":"JM Pita","year":"2023","unstructured":"Pita JM, Rasp\u00e9 E, Coulonval K, Decaussin-Petrucci M, Tarabichi M, Dom G, et al. CDK4 phosphorylation status and rational use for combining CDK4\/6 and BRAF\/MEK inhibition in advanced thyroid carcinomas. Front Endocrinol. 2023;14:1247542. https:\/\/doi.org\/10.3389\/fendo.2023.1247542.","journal-title":"Front Endocrinol"},{"key":"8892_CR38","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.171916","volume":"9","author":"D Zhao","year":"2024","unstructured":"Zhao D, Guo Y, Wei H, Jia X, Zhi Y, He G, et al. Multi-omics characterization of esophageal squamous cell carcinoma identifies molecular subtypes and therapeutic targets. JCI Insight. 2024;9:e171916. https:\/\/doi.org\/10.1172\/jci.insight.171916.","journal-title":"JCI Insight"},{"key":"8892_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102831","volume":"57","author":"M Liu","year":"2020","unstructured":"Liu M, An H, Zhang Y, Sun W, Cheng S, Wang R, et al. Molecular analysis of Chinese oesophageal squamous cell carcinoma identifies novel subtypes associated with distinct clinical outcomes. EBioMedicine. 2020;57:102831. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102831.","journal-title":"EBioMedicine"},{"key":"8892_CR40","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108599","volume":"41","author":"L Crozier","year":"2022","unstructured":"Crozier L, Foy R, Mouery BL, Whitaker RH, Corno A, Spanos C, et al. CDK4\/6 inhibitors induce replication stress to cause long-term cell cycle withdrawal. EMBO J. 2022;41:e108599. https:\/\/doi.org\/10.15252\/embj.2021108599.","journal-title":"EMBO J"},{"key":"8892_CR41","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature23449","volume":"548","author":"KJ Mackenzie","year":"2017","unstructured":"Mackenzie KJ, Carroll P, Martin C-A, Murina O, Fluteau A, Simpson DJ, et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature. 2017;548:461\u20135. https:\/\/doi.org\/10.1038\/nature23449.","journal-title":"Nature"},{"key":"8892_CR42","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nri3719","volume":"14","author":"V Hornung","year":"2014","unstructured":"Hornung V, Hartmann R, Ablasser A, Hopfner K-P. OAS proteins and cGAS: unifying concepts in sensing and responding to cytosolic nucleic acids. Nat Rev Immunol. 2014;14:521\u20138. https:\/\/doi.org\/10.1038\/nri3719.","journal-title":"Nat Rev Immunol"},{"key":"8892_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100789","volume":"8","author":"HC Puhr","year":"2023","unstructured":"Puhr HC, Prager GW, Ilhan-Mutlu A. How we treat esophageal squamous cell carcinoma. ESMO Open. 2023;8:100789. https:\/\/doi.org\/10.1016\/j.esmoop.2023.100789.","journal-title":"ESMO Open"},{"key":"8892_CR44","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Ng AWT, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94\u2013101. https:\/\/doi.org\/10.1038\/s41586-020-1943-3.","journal-title":"Nature"},{"key":"8892_CR45","doi-asserted-by":"publisher","first-page":"273","DOI":"10.20892\/j.issn.2095-3941.2022.0024","volume":"19","author":"W Liu","year":"2022","unstructured":"Liu W, Cui Y, Liu W, Liu Z, Xu L, Li E. Deep proteome profiling promotes whole proteome characterization and drug discovery for esophageal squamous cell carcinoma. Cancer Biol Med. 2022;19:273\u20137. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2022.0024.","journal-title":"Cancer Biol Med"},{"key":"8892_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53164-x","volume":"15","author":"G Jiang","year":"2024","unstructured":"Jiang G, Wang Z, Cheng Z, Wang W, Lu S, Zhang Z, et al. The integrated molecular and histological analysis defines subtypes of esophageal squamous cell carcinoma. Nat Commun. 2024;15:8988. https:\/\/doi.org\/10.1038\/s41467-024-53164-x.","journal-title":"Nat Commun"},{"key":"8892_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9971","volume":"6","author":"D Aran","year":"2015","unstructured":"Aran D, Sirota M, Butte AJ. Systematic pan-cancer analysis of tumour purity. Nat Commun. 2015;6:8971. https:\/\/doi.org\/10.1038\/ncomms9971.","journal-title":"Nat Commun"},{"key":"8892_CR48","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s12276-025-01395-3","volume":"57","author":"A Shanabag","year":"2025","unstructured":"Shanabag A, Armand J, Son E, Yang HW. Targeting CDK4\/6 in breast cancer. Exp Mol Med. 2025;57:312\u201322. https:\/\/doi.org\/10.1038\/s12276-025-01395-3.","journal-title":"Exp Mol Med"},{"key":"8892_CR49","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2159-8290.cd-19-1390","volume":"10","author":"SA Wander","year":"2020","unstructured":"Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor\u2013positive metastatic breast cancer. Cancer Discov. 2020;10:1174\u201393. https:\/\/doi.org\/10.1158\/2159-8290.cd-19-1390.","journal-title":"Cancer Discov"},{"key":"8892_CR50","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abq4293","volume":"8","author":"I Soria-Bretones","year":"2022","unstructured":"Soria-Bretones I, Thu KL, Silvester J, Cruickshank J, Ghamrasni SE, Ba-alawi W, et al. The spindle assembly checkpoint is a therapeutic vulnerability of CDK4\/6 inhibitor\u2013resistant ER+ breast cancer with mitotic aberrations. Sci Adv. 2022;8:eabq4293. https:\/\/doi.org\/10.1126\/sciadv.abq4293.","journal-title":"Sci Adv"},{"key":"8892_CR51","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1083\/jcb.201212110","volume":"202","author":"A Ivanov","year":"2013","unstructured":"Ivanov A, Pawlikowski J, Manoharan I, van Tuyn J, Nelson DM, Rai TS, et al. Lysosome-mediated processing of chromatin in senescence. J Cell Biol. 2013;202:129\u201343. https:\/\/doi.org\/10.1083\/jcb.201212110.","journal-title":"J Cell Biol"},{"key":"8892_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s41021-024-00298-5","volume":"46","author":"Y Okada","year":"2024","unstructured":"Okada Y, Chikura S, Kimoto T, Iijima T. CDK4\/6 inhibitor-induced bone marrow micronuclei might be caused by cell cycle arrest during erythropoiesis. Genes Environ. 2024;46:3. https:\/\/doi.org\/10.1186\/s41021-024-00298-5.","journal-title":"Genes Environ"},{"key":"8892_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102231","volume":"52","author":"CM Roggero","year":"2025","unstructured":"Roggero CM, Ghosh AB, Devineni A, Ma S, Blatt E, Raj GV, et al. CDK4\/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer. Transl Oncol. 2025;52:102231. https:\/\/doi.org\/10.1016\/j.tranon.2024.102231.","journal-title":"Transl Oncol"},{"key":"8892_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36195-8","volume":"14","author":"KM MacDonald","year":"2023","unstructured":"MacDonald KM, Nicholson-Puthenveedu S, Tageldein MM, Khasnis S, Arrowsmith CH, Harding SM. Antecedent chromatin organization determines cGAS recruitment to ruptured micronuclei. Nat Commun. 2023;14:556. https:\/\/doi.org\/10.1038\/s41467-023-36195-8.","journal-title":"Nat Commun"},{"key":"8892_CR55","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1016\/j.molcel.2024.04.017","volume":"84","author":"T Takaki","year":"2024","unstructured":"Takaki T, Millar R, Hiley CT, Boulton SJ. Micronuclei induced by radiation, replication stress, or chromosome segregation errors do not activate cGAS-STING. Mol Cell. 2024;84:2203\u201313.e5. https:\/\/doi.org\/10.1016\/j.molcel.2024.04.017.","journal-title":"Mol Cell"},{"key":"8892_CR56","doi-asserted-by":"publisher","unstructured":"Zhang D, Liu Y, Zhu Y, Zhang Q, Guan H, Liu S, et al. A non-canonical cGAS\u2013STING\u2013PERK pathway facilitates the translational program critical for senescence and organ fibrosis. Nat Cell Biol. 2022. https:\/\/doi.org\/10.1038\/s41556-022-00894-z.","DOI":"10.1038\/s41556-022-00894-z"},{"key":"8892_CR57","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ni.3558","volume":"17","author":"Q Chen","year":"2016","unstructured":"Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS\u2013STING pathway of cytosolic DNA sensing. Nat Immunol. 2016;17:1142\u20139. https:\/\/doi.org\/10.1038\/ni.3558.","journal-title":"Nat Immunol"},{"key":"8892_CR58","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.immuni.2024.02.019","volume":"57","author":"S Dvorkin","year":"2024","unstructured":"Dvorkin S, Cambier S, Volkman HE, Stetson DB. New frontiers in the cGAS-STING intracellular DNA-sensing pathway. Immunity. 2024;57:718\u201330. https:\/\/doi.org\/10.1016\/j.immuni.2024.02.019.","journal-title":"Immunity"},{"key":"8892_CR59","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13046-025-03366-y","volume":"44","author":"V Singh","year":"2025","unstructured":"Singh V, Ubaid S, Kashif M, Singh T, Singh G, Pahwa R, et al. Role of inflammasomes in cancer immunity: mechanisms and therapeutic potential. J Exp Clin Cancer Res. 2025;44:109 https:\/\/doi.org\/10.1186\/s13046-025-03366-y.","journal-title":"J Exp Clin Cancer Res"},{"key":"8892_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14392","volume":"8","author":"JF Almine","year":"2017","unstructured":"Almine JF, O\u2019Hare CAJ, Dunphy G, Haga IR, Naik RJ, Atrih A, et al. IFI16 and cGAS cooperate in the activation of STING during DNA sensing in human keratinocytes. Nat Commun. 2017;8:14392. https:\/\/doi.org\/10.1038\/ncomms14392.","journal-title":"Nat Commun"},{"key":"8892_CR61","doi-asserted-by":"publisher","unstructured":"Moresi F, Noto F, Vasudevan J, Bisteau X, Adriani G, Pavesi A. Microphysiological systems in cancer research: advancing immunotherapy through tumor microenvironment-integrated organ-on-chip models. Adv Ther. 2025. https:\/\/doi.org\/10.1002\/adtp.202500098.","DOI":"10.1002\/adtp.202500098"},{"key":"8892_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123175","volume":"320","author":"J Vasudevan","year":"2025","unstructured":"Vasudevan J, Vijayakumar R, Reales-Calderon JA, Lam MSY, Ow JR, Aw J, et al. In vitro integration of a functional vasculature to model endothelial regulation of chemotherapy and T-cell immunotherapy in liver cancer. Biomaterials. 2025;320:123175. https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123175.","journal-title":"Biomaterials"},{"key":"8892_CR63","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, et al. CDK4\/6 inhibition triggers anti-tumour immunity. Nature. 2017;548:471\u20135. https:\/\/doi.org\/10.1038\/nature23465.","journal-title":"Nature"},{"key":"8892_CR64","doi-asserted-by":"publisher","first-page":"CD-17-0915","DOI":"10.1158\/2159-8290.cd-17-0915","volume":"8","author":"J Deng","year":"2017","unstructured":"Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, et al. CDK4\/6 inhibition augments anti-tumor immunity by enhancing T cell activation. Cancer Discov. 2017;8:CD-17-0915 https:\/\/doi.org\/10.1158\/2159-8290.cd-17-0915.","journal-title":"Cancer Discov"},{"key":"8892_CR65","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6:263 https:\/\/doi.org\/10.1038\/s41392-021-00658-5.","journal-title":"Signal Transduct Target Ther"},{"key":"8892_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01041-1","volume":"9","author":"NM Kettner","year":"2025","unstructured":"Kettner NM, Bui TN, Navarro-Yepes J, Ghotbaldini S, Quintela B, Luo CK, et al. IL-6 predicts CDK4\/6 inhibitor resistance, identifying STAT3 as a target in HR + \/HER2-negative metastatic breast cancer. npj Precis Oncol. 2025;9:260. https:\/\/doi.org\/10.1038\/s41698-025-01041-1.","journal-title":"npj Precis Oncol"},{"key":"8892_CR67","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ccell.2020.01.007","volume":"37","author":"B Salvador-Barbero","year":"2020","unstructured":"Salvador-Barbero B, \u00c1lvarez-Fern\u00e1ndez M, Zapatero-Solana E, Bakkali AE, Men\u00e9ndez MdelC, L\u00f3pez-Casas PP, et al. CDK4\/6 inhibitors impair recovery from cytotoxic chemotherapy in pancreatic adenocarcinoma. Cancer Cell. 2020;37:340\u201353.e6. https:\/\/doi.org\/10.1016\/j.ccell.2020.01.007.","journal-title":"Cancer Cell"},{"key":"8892_CR68","doi-asserted-by":"publisher","unstructured":"Li K, Liu C, Sui X, Li C, Zhang T, Zhao T, et al. An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer. Cell Stem Cell. 2025. https:\/\/doi.org\/10.1016\/j.stem.2025.05.011","DOI":"10.1016\/j.stem.2025.05.011"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08892-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08892-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08892-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:05:27Z","timestamp":1785452727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08892-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8892"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08892-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following financial interests\/personal relationships, which may be considered as potential competing interests: AP reports a relationship with AIM Biotech PTE.LTD. that includes: board membership and equity or stocks. AP has a patent licensed to AIM biotech. Other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"666"}}